Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Total Current Liabilities (2017 - 2025)

Cue Biopharma (CUE) has disclosed Total Current Liabilities for 9 consecutive years, with $13.5 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 1.42% to $13.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.5 million through Dec 2025, down 1.42% year-over-year, with the annual reading at $13.5 million for FY2025, 1.42% down from the prior year.
  • Total Current Liabilities hit $13.5 million in Q4 2025 for Cue Biopharma, down from $15.5 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $19.3 million in Q2 2025 to a low of $8.3 million in Q2 2022.
  • Historically, Total Current Liabilities has averaged $14.8 million across 5 years, with a median of $15.5 million in 2025.
  • Biggest five-year swings in Total Current Liabilities: tumbled 50.08% in 2022 and later surged 95.93% in 2023.
  • Year by year, Total Current Liabilities stood at $12.8 million in 2021, then dropped by 9.69% to $11.5 million in 2022, then soared by 47.91% to $17.1 million in 2023, then decreased by 19.86% to $13.7 million in 2024, then decreased by 1.42% to $13.5 million in 2025.
  • Business Quant data shows Total Current Liabilities for CUE at $13.5 million in Q4 2025, $15.5 million in Q3 2025, and $19.3 million in Q2 2025.